The current study was conducted to study the incidence of human papillomavirus (HPV)-associated nasopharyngeal carcinoma (NPC) in Southern China and the corresponding treatment outcome. METHODS: A retrospective chart review with a level of evidence of 4 was performed. RESULTS: Between 2000 and 2015, a total of 1328 patients with NPC were treated in 3 study institutes in Hong Kong and Foshan City in Guangdong Province, China. All tumors were undifferentiated, nonkeratinizing carcinoma, of which 91.9% were positive for the Epstein-Barr virus (EBV1) and 7.7% were positive for HPV/p16 (HPV1). Although coinfection with both viruses occurred only in 8 patients (0.6%), 94 patients had tumors that were EBV negative (EBV-) and HPV1. All patients were treated with intensity-modulated radiotherapy alone for American Joint Committee on Cancer stage I and II disease, and concurrent chemoradiotherapy for stage III and IV disease. With a median follow-up of 72.8 months, the authors found that the local recurrence rate was significantly lower for patients with tumors that were EBV-/HPV1 compared with patients with tumors that were EBV1/ HPV-(6.4% vs 13.8%; P 5 .03). Similar trends were observed for the 5-year disease-free survival rate (89.8% vs 70.8%; P 5.03) and 5-year overall survival rate (86% vs 72%; P 5.03). CONCLUSIONS: In regions that are endemic for NPC, the prevalence of EBV and HPV coinfection in patients with NPC is extremely low. Conversely, patients with EBV-/HPV1 NPC demonstrate significantly better local tumor control and survival after radiotherapy. Cancer 2018;124:530-6.
INTRODUCTION
Nasopharyngeal carcinoma (NPC) is unique among other head and neck malignancies with regard to its epidemiology, pathology, and treatment outcome. 1, 2 It is endemic in southern China, including Hong Kong, with a reported annual incidence of up to 50 cases per 100,000 population. 3 Nearly all tumors are undifferentiated, nonkeratinizing carcinoma, corresponding to the World Health Organization (WHO) type III. This is in contrast with nonendemic areas such as North America, where the incidence of WHO tumors of types I, II, and III is 25%, 12%, and 63%, respectively. 2 It is well recognized that NPC in endemic areas is almost universally associated with Epstein-Barr virus (EBV). Conversely, there has been an increasing incidence of human papillomavirus (HPV)-associated oropharyngeal carcinoma in European and American populations. 4, 5 With the corresponding differences in the demographics 6, 7 and treatment results 8 in this group of patients, questions have been raised regarding the role of this epitheliotropic virus in NPC. [9] [10] [11] However, to the best of our knowledge, studies to date have investigated NPC tumor tissues from nonendemic regions, and data from Southern China, where to our knowledge NPC is most endemic in the world, are lacking. The objective of the current study was to investigate the prevalence of HPV and NPC using tumor tissues from multiple centers in Southern China, where the disease is endemic.
MATERIALS AND METHODS
The current study was approved by the ethics committee of the institutional review board of the University of Hong Kong. We identified 1328 consecutive patients who were diagnosed and treated for NPC in 3 major institutes in Hong Kong and Foshan City in Guangdong Province between 2000 and 2015. All patients had histologically confirmed undifferentiated, nonkeratinizing carcinoma of the nasopharynx, and had tumor samples available for investigation. All patients underwent clinical examinations, including endoscopic assessment and biopsy for histological confirmation, contrastenhanced magnetic resonance imaging for staging purposes, and plasma EBV DNA for baseline assessment. Only patients with tumors arising from the nasopharynx were included. Written informed consent was obtained from patients regarding the use of the tumor tissue for research purposes and the surgeries performed as well as photos taken for the purpose of subsequent publication. For patients with NPC diagnosed between 2010 and 2015, endoscopy was repeated and an adequate volume of tumor was sampled. For patients presenting with recurrent tumor after receipt of previous radiotherapy, nasopharyngectomy specimens were sampled. All specimens were wrapped in aluminum foil and snap frozen to -808C in liquid nitrogen solution. For patients treated between 2000 and 2010, their tumor samples were retrieved from the tissue bank of the research laboratory of the corresponding hospital. Patients with nasopharyngeal tumors other than the undifferentiated, nonkeratinizing type; those with oropharyngeal or sinonasal tumors with endoscopic and radiological evidence of extension to the nasopharynx; those of an ethnicity other than Chinese and a place of origin from provinces other than Guangdong and Hong Kong; and those with incomplete follow-up information were excluded from the study. All patients with newly diagnosed tumors were treated with intensity-modulated radiotherapy, with concurrent chemoradiation using cisplatin for patients with locoregionally advanced disease. Surgical salvage was performed for patients with local tumor recurrence, and the choice of the approach depended on the location and extent of the tumor as well as surgical expertise available in the corresponding institute.
Detection of EBV-Encoded RNA in Tumor Tissue
In situ hybridization was performed for EBV-encoded RNA (EBER) using the fluorescein-conjugated EBV peptide nucleic acid (PNA) probe (Dako, Glostrup, Denmark), according to the manufacturer's protocol. The specimen was predigested with proteinase K followed by the application of hybridization solution with fluorescein-conjugated EBV nucleic acid probe. Alkaline-phosphatase-conjugated antibody to fluorescein isothiocyanate then was applied, followed by 5-bromo-4-chloro-3-indolyl-phosphate/4-nitroblue tetrazolium chloride that was combined with levamisole as the chromogen. The slides were counterstained with hematoxylin. For cells with a positive hybridization signal, the nuclei would be stained dark blue or black in color. For each specimen, positive and negative control slides were run using a positive control fluorescein-conjugated PNA probe (Dako) and a negative control fluorescein-conjugated PNA probe (Dako), respectively.
Detection of HPV and p16 in Tumor Tissue
All specimens were screened with RNA probes (Digene Hybrid Capture 2 HPV DNA test; Qiagen, Hilden, Germany) that detected 13 high-risk HPV types (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 , and 68) and 5 low-risk types (types 6, 11, 42, 43, and 44). The test used full genome RNA probes that were complementary to HPV DNA, specific antibodies, and chemiluminescent detection. After combining with the RNA probes, the target DNA-RNA hybrids were captured onto a solid phase that was coated with universal capture antibodies specific for DNA-RNA hybrids. The specimen matrix then was washed from the captured hybrids to remove the inhibitors. At the time of signal amplification, the captured DNA-RNA hybrids were detected with multiple antibodies that were conjugated to alkaline phosphatase. The results from the chemiluminescent reaction were interpreted automatically.
p16 (CDKN2A) overexpression was considered to be a surrogate marker for HPV infection because the oncoprotein E7 binds to retinoblastoma protein, releasing the transcription factor E2F that in turn upregulates p16 expression. Tumor specimens were tested for p16 immunohistochemistry. From each block of tissue, sections measuring 3 lm in thickness were prepared and treated with 3% hydrogen peroxide solution for 10 minutes to inactivate the endogenous peroxidase activity. The sections then were incubated with a protein blocker (Dako) for 20 minutes and subsequently incubated at 48C with a p16 (JC8) antibody (Santa Cruz Biotechnology, Santa Cruz, California) as the primary antibody. The specimens then were washed 3 times with phosphate-buffered saline (pH 7.2) and exposed to En Vision 1 secondary antibody (Dako) for 30 minutes, and subsequently immersed in a 3 0 ,3-diamidobenzidine tetrahydrochloride solution. The specimens then were counterstained with hematoxylin. According to the article published by Westra, 12 the specimens were scored based on strong nuclear/nuclear and cytoplasmic staining as follows: negative (0% to <5%), focal strong (5% to <50%), and diffuse strong (>50%). Tumors that demonstrated diffuse strong staining for p16 were considered positive.
Clinical Follow-Up
All patients were followed regularly and indefinitely after treatment of NPC. Endoscopic assessment of the nasopharynx was performed during follow-up at the outpatient clinic, and biopsy was performed of suspicious areas to rule out tumor recurrence. Plasma EBV DNA was monitored every 6 months. Contrast magnetic resonance imaging was performed every 6 months for the first 2 years after treatment and then yearly afterward.
Statistical Analysis
The clinical data forming the basis of the current study were collected prospectively and entered into the head and neck cancer database of the corresponding institute. The data were retrieved for analysis in the current study. Chi-square or Fisher exact tests were used to compare categorical variables, and Student t tests were used to compare continuous variables. One-way analysis of variance was used to compare between 2 groups. Overall survival (OS) was defined as the time from the first date of treatment to the date of last follow-up or death. Disease-free survival (DFS) was calculated from the first date of treatment until the date of disease recurrence or the last follow-up visit. Tumor recurrence was defined as the recurrence of disease after previous complete serological and radiological response after treatment. Local recurrence was diagnosed histologically from endoscopic biopsies obtained from the nasopharynx, whereas lymph node recurrence was confirmed cytologically by ultrasoundguided fine-needle aspiration. Distant failures, depending on the organs involved, were diagnosed by whole-body computed tomography, bone scintigraphy, or positron emission tomography. Kaplan-Meier survival curves were generated for OS, and the differences between groups were compared using the log-rank test. Data were analyzed using SPSS statistical software (version 18.0; IBM Corporation, Armonk, New York). A P of .05 was considered to be statistically significant.
RESULTS
During the investigational period, a total of 1864 patients with NPC who were treated in the study centers in Hong Kong and Foshan City were identified. Among these patients, 164 were excluded because of a pathology other than undifferentiated, nonkeratinizing carcinoma, 112 were excluded because of patients' noncompliance with the treatment protocol, and 260 were excluded because of defaulted follow-up after treatment or the presence of incomplete follow-up information from the database. Table 1 presents the patient and tumor characteristics of the 1328 patients who were included in the current study.
EBER Status
Among the 1328 specimens, 1221 (91.9%) were categorized as EBER positive; among the remaining 107 patients (8.1%), tumors were diagnosed as EBER negative. All tumors were confirmed to be undifferentiated, nonkeratinizing carcinoma on histological examination.
HPV Status
A total of 102 patients (7.7%) were HPV positive (HPV1), and all cases were found to be p16 positive by immunohistochemistry. Conversely, tumors that were negative for HPV all were found to be negative for p16.
Among the patients who were positive for HPV/ p16, approximately 92.2% (94 patients) were EBV negative (EBV-) ( Table 2) . Thirteen patients had tumors that were both EBV-and HPV-. Coinfection (EBV positive [EBV1]/HPV1) was present in only 8 of the 1328 patients (0.6%), for whom the demographic data and tumor characteristics were not found to be significantly different from those of the rest of the groups.
Treatment Outcome and Survival
Patients presenting with early-stage (American Joint Committee on Cancer stages I and II) NPC in various groups were: 1) EBV1/HPV-(470 of 1213 patients; 38.7%; 2) EBV1/HPV1 (4 of 8 patients; 50.0%); 3) EBV-/HPV1 (37 of 94 patients; 39.4%); and 4) EBV-/ HPV-(8 of 13 patients; 61.5%). There were no statistically significant differences noted with regard to smoking status between the various groups of patients, although there were fewer smokers in the EBV1/HPV1 group When the various disease stages were analyzed separately for the 2 groups of patients (Table 3) , patients with EBV-/HPV1 disease had better local tumor control for all stages of disease, reaching statistical significance for stage II (P 5.01) and stage IV (P 5.02). These patients also demonstrated a superior OS that was found to be statistically significant among those with stage II (P 5.04), stage III (P 5.03), and stage IV (P 5.03) disease. The Kaplan-Meier curve for the 5-year OS is shown in Figure  1 . A similar trend was observed for DFS (stage II: P 5.04; stage III: P 5.02; and stage IV: P 5.02, respectively). The For patients with tumors that were EBV1/HPV1, the local recurrence rate was 12.5% and the 5-year DFS and 5-year OS rates were 72% and 70%, respectively. These were not significantly different from those of patients whose tumors were HPV-. Compared with the patients with EBV-/HPV1 disease, the advantages in local tumor control and survival associated with the presence of HPV infection were lost in patients with coinfection, although the number of patients was too small for statistically meaningful analysis. DISCUSSION NPC is endemic in southern China, including Hong Kong, and affects up to 50 individuals per 100,000 population per year. 3 Unlike in nonendemic regions, >95% of the NPC cases in our locality are undifferentiated, nonkeratinizing carcinoma, and our previous study demonstrated that the majority of these tumors are EBV1. 13 The ubiquitous association of EBV with nonkeratinizing NPC suggests its oncogenic role in its pathogenesis.
In recent decades, there has been a major shift in the epidemiology of head and neck cancer, particularly oropharyngeal squamous cell carcinoma (OPSCC), in association with the increasing prevalence of HPV infection. In European and North American populations, there is a rising trend of oropharyngeal cancer, despite a decrease in the prevalence of cigarette smoking. 14, 15 Up to 70% of patients with oropharyngeal cancer have HPV detected in the genomic DNA of the tumor cells, and 90% of these are associated with the high-risk HPV types, particularly type 16. 16 These tumors are being recognized as a distinct clinical entity with unique biological behavior, and because of their significantly superior sensitivity to, and hence better prognosis after, chemoradiation, there has been growing enthusiasm for investigating the feasibility and safety of the de-escalation of treatment for HPVrelated cancer in the head and neck region. [17] [18] [19] As mentioned, HPV-related OPSCC with p16 overexpression is significantly more radiosensitive and carries a better prognosis compared with its non-HPVrelated counterpart. Because of the close proximity of the nasopharynx to the oropharynx, the possible role of HPV in NPC and its potential effect on treatment outcome has drawn much attention. To our knowledge, there are only a few reports to date regarding the association between HPV and NPC. Lo et al retrospectively studied 30 patients from the United States and found that WHO type I NPC is more commonly associated with HPV than WHO type II and type III NPC. 20 Dogan et al 21 investigated 90 patients with NPC and demonstrated HPV positivity in only 6 patients. The authors concluded that HPV may potentially confer a survival benefit similar to that of EBV. However, the major limitation of their study was that patients with keratinizing tumors were included, which may have influenced the survival outcome after treatment. Lin et al studied 2 cohorts of patients from Shantou, China and Stanford, California, and found that all the tumors in the cohort of 86 Chinese patients were negative for HPV. The HPV1 tumors were found only in white individuals, and there was a strong association with cigarette smoking. 22 Jiang et al investigated 86 patients with NPC who were treated at The University of Texas MD Anderson Cancer Center in Houston between 2000 and 2014 and reported that p16 overexpression was found to be associated with improved progression-free survival and locoregional control in patients with EBV1 NPC; they concluded that p16 expression may complement EBV status in predicting treatment outcomes for patients with NPC. 23 Data from the nonendemic countries of Asia also demonstrated that HPV/p16 expression is uncommon in patients with NPC. 24, 25 There are reports from other nonendemic regions of the world demonstrating a possible association between HPV and NPC and its potential influence on carcinogenesis. 26 In addition, there are postulations regarding the biological plausibility of the vertical, perinatal transmission of oncogenic HPV to newborns that puts them at risk of developing NPC subsequently, and hence the potential role of community control of HPV infection and newborn vaccination. 27 To our knowledge, the current study is the largest multicenter report to date investigating the association between HPV and NPC in the Guangdong region, which is an endemic region for NPC with what to our knowledge is the highest incidence of the disease in the world. The current study results add important information to the database published in the literature, particularly the inconsistencies in the reported incidence of viral coinfection with EBV and HPV in patients with NPC. 9, 20, 28, 29 Patients with nasopharyngeal tumors of the keratinizing type (WHO type I) were excluded from the current study because we believe that these tumors are biologically and pathologically distinct from the undifferentiated nonkeratinizing type that constitutes >90% of NPC in our endemic region. By studying 1328 consecutive patients with histologically proven NPC of the undifferentiated, nonkeratinizing cell type (WHO type III), we found that EBV still is the most common oncogenic virus associated with the cancer, with approximately 91.9% of the tumor specimens being EBV1. Conversely, the overall incidence of NPC associated with HPV infection was only 7.7%, and the majority of these tumors were EBV-. The chance of tumors having coinfection with both EBV and HPV is extremely low, and this is in accordance with the findings of other groups. Coinfection was found to occur in only 8 patients (0.6%) in the current study. To the best of our knowledge, the question of whether EBV and HPV coinfection in patients with NPC are mutually exclusive remains unproven. 10, 30 However, what is known is that latent membrane protein 1, which is an oncoprotein of the EBV latent gene product expressed by the majority of NPC tumors, blocks p16 expression and inhibits its downstream effectors. 31, 32 However, consideration has to be given to the fact that the prevalence of HPV-associated head and neck cancer in the locality is significantly lower compared with that of Europe and North America, with our recent report demonstrating that only approximately 20.8% of the cases of OPSCC in southern China are associated with HPV. 33 Although we demonstrated that our patients with HPV-associated OPSCC had a significantly better prognosis after receipt of chemoradiation, to our knowledge the potential survival advantage for patients with HPV1/EBV1 NPC is not apparent.
Conversely, the percentage of HPV-positive tumors is significantly higher in patients who are EBV-. Patients with EBV-/HPV1 tumors have significantly better local tumor control and 5-year DFS as well as OS compared with patients in other subgroups. This observation suggests that HPV-associated nasopharyngeal tumor is a distinct entity that behaves in a manner similar to that of its HPV-associated OPSCC counterpart. 29 The major limitation of the current study was the variation in treatment protocols, including radiation techniques and the choice of systemic chemotherapy, over the investigational period and between the different institutions. Moreover, despite the large total sample size of the current study, some subgroups had too few patients for comparison with adequate statistical power. Further clinical studies with larger sample sizes for patients with HPV1 tumors are necessary to confirm the observations of the current study and prove the hypothesis.
Conclusions
In regions that are endemic for NPC such as southern China, the prevalence of EBV and HPV coinfection in patients with NPC is extremely low. Conversely, patients with EBV-/HPV1 nasopharyngeal tumors demonstrate a significantly better local tumor control rate and survival after radiotherapy.
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